Nadolol (PS-527) の狭心症に対する効果

多施設二重盲検群間比較試験による検討

抄録

The anti-anginal effect of nadolol was compared with that of propranolol . The present study was carried out as a multicenter, double-blind group-comparison, with the following results.
1. The subjects were primarily patients with effort angina. Nadolol was administered in a single daily dose of 30 mg, while propranolol was administered in a daily dosage of 30 mg given in 3 divided doses, for 4 weeks each. When no effect was noted by the end of 2 weeks of treatment, the daily dosage of each was increased to 60 mg.
2. There was no significant difference between the nadolol and propranolol groups in terms of clinical usefulness. The usefulness rate in the nadolol group was 80.0% (28/35), while it was 64.9% (24/37) in the propranolol group.
3. In the evaluation performed by the physician-in-charge, the global improvement rates were 77.1% (27/35) for nadolol and 62.2% (23/37) for propranolol groups. There was no significant difference between these two rates. However, when only the cases of effort angina were considered, nadolol appeared to be superior to propra nolol.
4. Heart rate was found to be significantly decreased in both the nadolol and prop-ranolol groups from the end of the first week of treatment in comparison with the rate prior to the drug treatment period. As for blood pressure, in the propranolol group significant decrease was seen only in the systolic blood pressure at the end of the 4th week of treatment, whereas in the nadolol group significant decrease was seen in both the systolic and diastolic blood pressures at the end of 2 weeks of treatment.
5. Concerning the safety of the drug regimen, the percentages of patients not show ing any side effects of the drug were 86.0% (43/50) for the nadolol group and 92.3% (48/52) for the propranolol group.This difference was not statistically significant.
In consideration of the fact that the nodolol regimen of a single daily dose gave these good results, it is concluded that nadolol is a more useful drug than proprano-lol for the clinical treatment of patients with angina pectoris.